Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Jennifer Yee1, Wu Gong2, Jula Inrig2
1Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
Key Points:
Sparsentan lowered proteinuria, with more frequent complete remission of proteinuria versus irbesartan in patients with genetic forms of FSGS. Fewer patients with genetic forms of FSGS progressed to the composite kidney endpoint with sparsentan versus irbesartan. Consistent with the overall DUPLEX population, the results support sparsentan's antiproteinuric benefit in patients with genetic forms of FSGS.
Background:
FSGS is a podocytopathy that is diagnosed based on characteristic histopathologic lesions. Certain forms of FSGS with underlying genetic variants associated with the disease, including variants in podocyte proteins, as well as apolipoprotein L1 ( APOL1 ) risk alleles, and variants in collagen type 4 α 3, α 4, and α 5 ( COL4A3-5 ) proteins, are typically resistant to current treatments.
Methods:
The DUPLEX clinical trial assessed the efficacy and safety of sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with biopsy-proven or genetic FSGS (gFSGS) and demonstrated a greater antiproteinuric effect over 108 weeks compared with the active control irbesartan. This post hoc , exploratory analysis assessed the efficacy of sparsentan in the subset of patients enrolled in DUPLEX who had pathogenic variants in genes coding for podocyte proteins, COL4A3-5 variants, and APOL1 high-risk genotypes, all together referred to as gFSGS.
Results:
Next-generation sequencing identified 31 patients with podocyte gene variants, 25 with COL4A3-5 gene variants, and 14 with APOL1 high-risk genotypes. Baseline characteristics varied between genetic subgroups, with slightly younger patients, on average, in the podocyte gene variant group, and more African American patients in the APOL1 high-risk genotype group. In this exploratory analysis, sparsentan treatment resulted in substantial and sustained proteinuria reductions and numerically more frequent complete remission of proteinuria compared with irbesartan, consistent with observations in the full DUPLEX study population. Moreover, a lower proportion of sparsentan-treated versus irbesartan-treated patients reached composite kidney endpoints.
Conclusions:
These findings support sparsentan's antiproteinuric benefit in patients with gFSGS, a subgroup that is often resistant to other therapeutic interventions.
Clinical Trial Registry Name And Registration Number:
Clinicaltrials.gov, NCT03493685 .
More Related Videos
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:28Renal Drug Excretion: Tubular Secretion
01:06Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
01:02Renal Drug Excretion: Glomerular Filtration
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics